Research Paper Volume 15, Issue 21 pp 11985—11993

Inhibition of keloid by 32P isotope radiotherapy through suppressing TGF-β/Smad signaling pathway

Long Xie1, , Liqun Huang1, , Guanjie Zhang1, , Yingrui Su1, ,

  • 1 Department of Nuclear Medicine, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China

Received: August 4, 2023       Accepted: September 27, 2023       Published: October 31, 2023
How to Cite

Copyright: © 2023 Xie et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Background: Keloid seriously affects the appearance, and is accompanied by some symptoms including pain, burning, itching. Radioactive nuclides such as 32P have been proved to be effective in inhibiting the formation of keloid, but the mechanism remains unclear.

Methods: The keloid animal model was established through keloid tissues implantation. Hematoxylin-Eosin (HE) and Masson staining were performed to investigate histological changes and collagen deposition. The mRNA and protein expression were assessed using RT-PCR and western blotting, respectively. Cell apoptosis and cycle were evaluated through flow cytometry.

Results: Both 32P isotope injection and skin path significantly reduced the size of keloid, and inhibited TGF-β/Smad signaling pathway. SRI-011381, the agonist of TGF-β/Smad signaling pathway, markedly reversed the influence of 32P isotope on cell proliferation, cell apoptosis, cell cycle of LNCaP cells and TGF-β/Smad signaling pathway.

Conclusions: 32P isotope injection and skin path greatly reduced the size of keloid, and the TGF-β/Smad signaling pathway was remarkably inhibited by 32P isotope treatment. The regulation of dermal fibroblast by 32P isotope was reversed by SRI-011381. 32P isotope might inhibit keloid through suppressing TGF-β/Smad signaling pathway. Our study provides a novel therapeutic strategy for the treatment of keloid.


HE: Hematoxylin-Eosin; RT-PCR: Reverse transcription-polymerase chain reaction; miRNAs: MicroRNAs; EMT: epithelial mesenchymal transition.